Terrance H Gregg Net Worth

The estimated Net Worth of Terrance H Gregg is at least 82.9 百万$ dollars as of 16 July 2018. Terrance Gregg owns over 10,000 units of Dexcom Inc stock worth over 3,483,891$ and over the last 19 years Terrance sold DXCM stock worth over 79,396,112$.

Terrance Gregg DXCM stock SEC Form 4 insiders trading

Terrance has made over 106 trades of the Dexcom Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Terrance sold 10,000 units of DXCM stock worth 995,600$ on 16 July 2018.

The largest trade Terrance's ever made was selling 150,000 units of Dexcom Inc stock on 18 August 2014 worth over 6,691,500$. On average, Terrance trades about 15,348 units every 14 days since 2005. As of 16 July 2018 Terrance still owns at least 50,882 units of Dexcom Inc stock.

You can see the complete history of Terrance Gregg stock trades at the bottom of the page.

What's Terrance Gregg's mailing address?

Terrance's mailing address filed with the SEC is C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO, CA, 92121.

Insiders trading at Dexcom Inc

Over the last 19 years, insiders at Dexcom Inc have traded over 724,717,982$ worth of Dexcom Inc stock and bought 165,450 units worth 3,489,100$ . The most active insiders traders include Sean Carney、Kim D Blickenstaff、Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of 892,438$. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth 29,458$.

What does Dexcom Inc do?

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.

Complete history of Terrance Gregg stock trades at Dexcom Inc

Dexcom Inc executives and stock owners

Dexcom Inc executives and other stock owners filed with the SEC include:

• Kevin Sayer,
  Chairman of the Board, President, Chief Executive Officer
• Quentin Blackford,
  Chief Financial Officer, Chief Operating Officer
• Richard Doubleday,
  Executive Vice President, Chief Commercial Officer
• Andrew Balo,
  Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development
• Steven Pacelli,
  Executive Vice President - Strategy and Corporate Development
• Donald Abbey,
  Executive Vice President - Quality and Regulatory Affairs
• Kevin Ronald Sayer,
  Exec. Chairman, CEO & Pres
• Jacob Steven Leach,
  Exec. VP & CTO
• Bridgette Heller,
  Independent Director
• Mark Foletta,
  Lead Independent Director
• Eric Topol,
  Independent Director
• Jay Skyler,
  Independent Director
• Nicholas Augustinos,
  Independent Director
• Steven Altman,
  Independent Director
• Barbara Kahn,
  Independent Director
• Richard Collins,
  Independent Director
• Kyle Malady,
  Independent Director
• Karen Dahut,
  Independent Director
• Shelly Selvaraj,
  Senior Vice President - Information Technology
• Jeffrey Moy,
  Senior Vice President - Operations
• Jereme Sylvain,
  Senior Vice President - Finance, Chief Accounting Officer
• Patrick Murphy,
  Executive Vice President, Chief Legal Officer
• Jake Leach,
  Executive Vice President, Chief Technology Officer
• Shelly Ramasamy Selvaraj,
  Sr. VP of Information Technology
• Donald M. Abbey,
  Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs
• Steven R. Pacelli,
  Exec. VP & MD of Dexcom Ventures
• Andrew K. Balo,
  Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel.
• Sadie M. Stern,
  Exec. VP & Chief HR Officer
• Chad M. Patterson,
  Exec. VP of Global Marketing
• Sean Christensen,
  Director of Corp. Affairs & Head of Investor Relations
• Jereme M. Sylvain,
  Exec. VP, CFO & Chief Accounting Officer
• John Lister,
  VP, Legal Affairs
• Terrance H Gregg,
  Director
• Jess Roper,
  VP, CFO
• Jorge A Valdes,
  Vice President of Engineering
• Girish Naganathan,
  EVP Chief Technology Officer
• Heather S Ace,
  SVP Human Resources
• Kevin M Sun,
  VP, Corp Controller & Treasury
• Jonathan T Md Lord,
  Director
• Glen D Nelson,
  Director
• Peter Gerhardsson,
  VP, Int'l Business Development
• David Carner,
  VP, Quality Assurance
• Laura Johnson,
  V.P., Intellectual Property
• Martin Doordan,
  Director
• Sean Carney,
  Director
• John Riolo,
  VP of Quality Assurance
• Claudia Graham,
  VP, Marketing
• Donald A Lucas,
  Director
• Donald L Lucas,
  Director
• Mark Brister,
  VP, Advanced Development Teams
• Richard Yang,
  V.P., Strategic Affairs
• James H Brauker,
  VP, Research & Development
• Rodney L Kellogg,
  Vice President of Sales
• Andrew P Rasdal,
  President and CEO
• Steven J Kemper,
  Chief Financial Officer
• Kim D Blickenstaff,
  Director
• Tae Andrews,
  Vice President of Marketing
• Paul Travelers Companies In...,
  
• Pincus Private Equity Viii ...,
  
• Brenton Karl Ahrens,
  Director
• Nancy Sfog City Management ...,
  
• Equity Partners Ii Llccanaa...,
  
• Paul Travelers Companies In...,
  
• Eric A Charmers Landing Llc...,
  
• Scott Lwindamere Llcwindame...,
  
• Equity Partners Ii Llc Waub...,
  
• Teri L Lawver,
  EVP Chief Commercial Officer
• Paul R Flynn,
  EVP Global Revenue
• Matthew Vincent Dolan,
  EVP Strategy and Corporate Dev
• Sumi Shrishrimal,
  SVP Chief Risk Officer
• Chad Patterson,
  EVP Global Marketing
• Barry J. Regan,
  EVP Operations
• Jacob Steven Leach,
  EVP, Chief Operating Officer
• Rimma Driscoll,
  Director
• Michael Jon Brown,
  EVP, Chief Legal Officer
• Sadie Stern,
  EVP, Chief HR Officer